Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers-Reference-Cited by-同舟云学术

Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers

Published:2014-07-09 Issue:5 Volume:29 Page:459-469
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum. Psychopharmacol Clin Exp

Author:

Cabaleiro Teresa¹,Ochoa Dolores¹,López-Rodríguez Rosario²³,Román Manuel¹,Novalbos Jesús¹,Ayuso Carmen⁴⁵,Abad-Santos Francisco¹³

Affiliation:

1. Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto Teófilo Hernando; Instituto de Investigación Sanitaria Princesa (IP); Madrid Spain

2. Liver Unit, Gastroenterology Service, Hospital Universitario de La Princesa; Instituto de Investigación Sanitaria Princesa (IP); Madrid Spain

3. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd); Instituto de Salud Carlos III; Madrid Spain

4. Department of Genetics and Genomics; Instituto de Investigación Sanitaria Fundación Jiménez Díaz; Madrid Spain

5. Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER); Instituto de Salud Carlos III; Madrid Spain

Funder

Fondo de Investigaciones Sanitarias of Instituto de Salud Carlos III

Fundaciï¿½n Teï¿½filo Hernando

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology

Reference52 articles.

1. Evaluating a newly developed pharmacogenetic array: screening in a Spanish population;Almoguera;Pharmacogenomics,2010

2. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment;Almoguera;Pharmacogenet Genomics,2013a

3. Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population;Almoguera;Pharmacogenomics J,2013b

4. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102 T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study;Angelucci;J Alzheimers Dis,2009

5. Differences in cytochrome P450-mediated pharmacokinetics between Chinese and Caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling;Barter;Clin Pharmacokinet,2013

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review;Journal of Psychiatric Research;2024-06

2. Exploratory focused pharmacogenetic testing reveals novel markers associated with risperidone pharmacokinetics in Saudi children with autism;Frontiers in Pharmacology;2024-02-05

3. Physiologically‐based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate;Clinical and Translational Science;2023-01-19

4. Pharmacogenetics and Schizophrenia—Can Genomics Improve the Treatment with Second-Generation Antipsychotics?;Biomedicines;2022-12-07

5. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine;Expert Opinion on Drug Metabolism & Toxicology;2022-11-02